Triasima Portfolio Management inc. Makes New Investment in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Triasima Portfolio Management inc. purchased a new stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 510 shares of the medical equipment provider’s stock, valued at approximately $266,000.

Several other large investors have also made changes to their positions in ISRG. Berbice Capital Management LLC bought a new stake in Intuitive Surgical in the fourth quarter worth approximately $26,000. Godsey & Gibb Inc. lifted its stake in shares of Intuitive Surgical by 140.0% in the 3rd quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 35 shares during the last quarter. MidAtlantic Capital Management Inc. bought a new stake in Intuitive Surgical in the third quarter worth $33,000. Decker Retirement Planning Inc. acquired a new position in Intuitive Surgical during the fourth quarter worth $36,000. Finally, Capital Performance Advisors LLP bought a new position in Intuitive Surgical during the third quarter valued at about $38,000. Institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Stock Performance

Shares of Intuitive Surgical stock opened at $582.98 on Friday. Intuitive Surgical, Inc. has a twelve month low of $364.17 and a twelve month high of $616.00. The firm has a market cap of $207.65 billion, a P/E ratio of 90.95, a price-to-earnings-growth ratio of 5.51 and a beta of 1.39. The firm’s 50-day simple moving average is $554.03 and its 200-day simple moving average is $513.12.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on ISRG. Barclays upped their price target on Intuitive Surgical from $610.00 to $674.00 in a research note on Monday, January 27th. Truist Financial increased their price target on Intuitive Surgical from $640.00 to $666.00 and gave the company a “buy” rating in a report on Friday, January 24th. Oppenheimer restated a “market perform” rating on shares of Intuitive Surgical in a research note on Friday, October 18th. Erste Group Bank upgraded shares of Intuitive Surgical from a “hold” rating to a “buy” rating in a report on Tuesday, November 19th. Finally, Robert W. Baird raised their price target on Intuitive Surgical from $503.00 to $565.00 and gave the company an “outperform” rating in a research report on Thursday, October 17th. One analyst has rated the stock with a sell rating, five have given a hold rating and sixteen have given a buy rating to the stock. According to MarketBeat, Intuitive Surgical has an average rating of “Moderate Buy” and a consensus price target of $613.10.

Insider Activity

In other news, Director Amal M. Johnson sold 4,635 shares of the business’s stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $566.60, for a total value of $2,626,191.00. Following the sale, the director now owns 12,275 shares in the company, valued at approximately $6,955,015. The trade was a 27.41 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Jamie Samath sold 94 shares of the business’s stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $571.11, for a total transaction of $53,684.34. Following the completion of the transaction, the chief financial officer now owns 2,630 shares in the company, valued at approximately $1,502,019.30. This trade represents a 3.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 5,940 shares of company stock worth $3,333,485. Company insiders own 0.90% of the company’s stock.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.